Acino ? Delivering Health

More documents

Recommendations

Info

Agenda 09:30 – 12:30 Welcome Robert Schmid 12:30 - 14:00 Lunch Acino - leading in technologies Dr. Jean-Daniel Bonny How our pipeline boosts growth Dr. Jean-Daniel Bonny Coffee break Successful in emerging markets in BtC Ruud van Anraat How to escape price pressure in BtB Ruud van Anraat Technical marketing and operations: Strategy and opportunities Dr. Jürgen Betzing 14:00 - 16:00 Facility tour (production / QC labs) 16:00 - 17:00 Financials Robert Schmid Summary and strategy Peter Burema 2
Acino – drug delivery specialist, marketer and partner The Acino Group is headquartered in Basle, currently employs approximately 850 staff and generated annual net revenues of about EUR 129 million in the first half-year 2012. Acino Holding Ltd., the Group’s parent, is listed on the SIX Swiss Exchange (SIX: ACIN). Acino is specialized: on the development, registration, manufacture and marketing of established and innovative pharmaceuticals using advanced and refined drug delivery technologies. Under the brand “Acino Switzerland”, Acino markets Swiss-quality medicines in up and coming economies, currently in 80 countries in the Middle East, Africa, Latin America and Asia. Acino continues to evaluate both opportunities for organic growth and acquisitions at a strategic and operational level, so as to advance its market position as a leading provider of pharmaceutical specialties 3
Page 1: Acino - Delivering Health Investor
Page 5 and 6: Acino’s growth drivers Fully expl
Page 7 and 8: Technology platform Oral modified r
Page 9 and 10: Oral modified release forms MUPS (M
Page 11 and 12: Technology platform Oral dispersibl
Page 13 and 14: Technology platform Transdermal sys
Page 15 and 16: Transdermal systems Why transdermal
Page 17 and 18: Technology platform Extended releas
Page 19 and 20: Extended release parenterals Advant
Page 21 and 22: Development projects Ferrous sulfat
Page 23 and 24: Development projects Rivastigmine T
Page 25 and 26: Development projects Goserelin & le
Page 27 and 28: Development projects Goserelin 1 &
Page 29 and 30: Development projects Leuprorelin 1
Page 31 and 32: Acino’s development pipeline Stat
Page 33 and 34: Acino - Delivering Health Thank you
Page 35 and 36: Entering emerging markets / “Swis
Page 37 and 38: Acino Switzerland 2009 BtC markets
Page 43 and 44: Opportunities Products with added v
Page 45 and 46: Acino Switzerland: Product Portfoli
Page 47 and 48: Acino portfolio Roll-out in new ter
Page 49 and 50: Criteria for selecting products for
Page 51 and 52: Acino’s business model (example)
Page 53 and 54:
Optimized BtB Concept - Geographica
Page 55 and 56:
Technical Marketing and Operations:
Page 57 and 58:
Acino’s production importance Tec
Page 59 and 60:
Production Technologies: Value for
Page 61 and 62:
Pellets Innovative technologies for
Page 63 and 64:
Pellet Projects High volume project
Page 65 and 66:
Granulates Hot melt granulation Sp
Page 67 and 68:
Manufacturing Process 67
Page 70 and 71:
Implants Implant manufacturing capa
Page 72 and 73:
Opportunity: High Quality Service S
Page 74 and 75:
Summary Focus on niche technologies
Page 76 and 77:
Competitive advantage factor: HighT
Page 78 and 79:
Micro Error Tracking System (METS)
Page 80 and 81:
Strategy to cope with declining mar
Page 82 and 83:
Financials Robert Schmid, Head of I
Page 84 and 85:
Promising potential areas of synerg
Page 86 and 87:
Reduced currency exposure Mepha / C
Page 88 and 89:
Summary and strategy Peter Burema,
Page 90 and 91:
Acino’s growth drivers Fully expl
Page 92 and 93:
Geographic break-down of revenue DE
Page 94:
Acino - Delivering Health Thank you
show all

Acino ? Delivering Health

Create successful ePaper yourself

Delete template?

Save as template?